

## Technology Advisory Interests Register

**Topic: Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia  
[ID1627]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	TAC Committee Member	Financial	Ongoing work with Novartis US regarding asciminib for newly diagnosed chronic myelogenous leukemia	27/02/2026	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal
David Meads	TAC Committee Member	Non-financial professional	University of Leeds has received funding from BMS for trial research relating to a different therapy in multiple myeloma	05/03/2026	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Dr Andrew King	Expert	Direct - financial	Servier – educational talks – total £1890. Subject: ivosidenib/azacitidine Brancaster Pharma Ltd – remote advisory board. Total £500	30/09/2025	It was agreed that Dr King's declaration would not prevent them from providing expert advice to the committee
			<b>educational talks:</b> Pfizer, £900. Topic: Elranatamab in myeloma; Inotuzumab in acute lymphoblastic leukaemia	09/04/2026	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p><b>Advisory Board:</b> Autolus £2100 (discussion of CAR-T in the treatment of acute lymphoblastic leukaemia)</p> <p><b>Travel support to conferences:</b> Amgen, Jazz Pharmaceuticals</p> <p><b>Janssen:</b> Principal Investigator for 89853413AML1001 and cAMeLot-2 trials (no payment received; running trial locally at my hospital)</p> <p>Member of the AML research committee</p>		
Professor Steven Knapper	Expert	Direct - financial	I have engaged in consultation activities with Brancaster Pharma over the last 12 months in the run up to this NICE submission, regarding the product featured in this appraisal. This included an online advisory board meeting on Feb 3rd, 2025, along with a number of other UK AML-treating colleagues for which an honorarium payment was made for which I received a payment of £500.	30/09/2025	It was agreed that Professor Knapper's declaration would not prevent them from providing expert advice to the committee
			On committee for UK research on AML	09/04/2026	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Adam Claxton	Expert		<p>Nominating organisation (Blood Cancer UK) has received the following:</p> <p>Pfizer - £43 in travel expenses, £810 CEO consultancy, £30,000 Blood Cancer UK Industry Collaborative</p> <p>BMS - £25,000 CTSS, £1,666.67 consultancy</p> <p>Daiichi Sankyo - £5,000 event sponsorship</p> <p>Novartis - £30,000 direct referral grant, £40,000 CNS programme of support grant, £3,500 donation in memory of an employee, £50,000 HCP improvement programme</p>	12/02/2026	It was agreed that Adam's declaration would not prevent them from providing expert advice to the committee